Journal article
Canadian Cohort Expanded-Access Program of Nivolumab Plus Ipilimumab in Advanced Melanoma.
Abstract
Background: The combination of nivolumab and ipilimumab is approved in several jurisdictions (United States, European Union, Canada) for the first-line treatment of patients with advanced melanoma. CheckMate 218 is a North American expanded-access program (EAP) of nivolumab plus ipilimumab in patients with advanced melanoma. Here, we report safety and survival outcomes for the Canadian cohort in the eap. Methods: Eligible patients were those 18 …
Authors
Hogg D; Monzon JG; Ernst S; Song X; McWhirter E; Savage KJ; Skinn B; Romeyer F; Smylie M
Journal
Curr Oncol, Vol. 27, No. 4, pp. 204–214
Publication Date
August 1, 2020
DOI
10.3747/co.27.5985